MYCT1 Modulation for Angiogenesis Control and Immune Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in addressing tumor angiogenesis and immune exhaustion, with anti-angiogenesis agents showing limited efficacy and immune checkpoint inhibitors (ICIs) facing resistance and immune-suppressive microenvironments in tumors.
Innovation Solution
Targeting MYCT1 expression and activity in endothelial cells to down-regulate angiogenesis and reprogram tumor immunity, enhancing high endothelial venule formation and promoting an anti-tumor immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-angiogenesis agents are used to deprive tumor nutrition, then tumor growth is inhibited, but tumors develop resistance and become resistant
Solution Approach 1:
The patent segments the anti-angiogenesis approach by identifying and targeting multiple distinct molecular pathways (VEGF pathway, Ang/Tie pathway, PDGF pathway, FGF pathway) rather than relying on a single agent. This multi-target strategy prevents tumors from developing resistance through a single mechanism, thereby improving therapeutic reliability and extending effective treatment duration.
Solution Approach 2:
The invention employs composite therapeutic strategies that combine multiple anti-angiogenic mechanisms acting on different pathways simultaneously. By integrating inhibitors targeting VEGF, Ang/Tie, PDGF, and FGF pathways, the treatment creates a composite effect that overcomes resistance development and maintains prolonged therapeutic efficacy.
2Reliability
If immune checkpoint inhibitors are used to unleash effector immune cells, then long-lasting clinical activity is achieved, but tumors develop secondary resistance due to defects in antigen-presenting machinery
Solution Approach 1:
The patent segments the immune response by addressing multiple defective components separately: antigen-presenting machinery defects, coinhibitory molecule overexpression, and immune exhaustion. By targeting each segment with specific therapeutic interventions, the treatment restores comprehensive immune function rather than relying on a single checkpoint pathway, thereby extending durable response duration.
Solution Approach 2:
The invention implements a universal immune reprogramming strategy that simultaneously corrects multiple immune defects (antigen presentation, T cell activation, and coinhibitory signaling) through coordinated therapeutic actions. This multi-functional approach restores overall immune system capability against tumor antigens, maintaining long-lasting clinical activity despite initial resistance mechanisms.
3Productivity
If tumors hijack angiogenesis for survival, then tumor proliferation is supported, but proangiogenic factors become dysregulated
Solution Approach 1:
The patent extracts and removes the dysregulated proangiogenic signaling from the tumor microenvironment by simultaneously inhibiting multiple angiogenic pathways (VEGF, Ang/Tie, PDGF, FGF). This extraction of pathological signaling restores normal regulatory control over angiogenesis, preventing tumor-driven dysregulation while maintaining essential physiological angiogenesis.
Solution Approach 2:
The invention changes the regulatory parameters of proangiogenic factors by applying targeted inhibition to multiple pathways, thereby shifting the system from a tumor-driven dysregulated state to a physiologically regulated state. This parameter modification restores proper control mechanisms over angiogenic factor expression and activity.
4Object-affected harmful factors
If tumors create immune-suppressive microenvironment, then immune exhaustion is induced, but anti-tumor immune response is suppressed
Solution Approach 1:
The patent converts the harmful immune-suppressive microenvironment into a beneficial anti-tumor immune contexture by reversing the pathological conditions. Through multi-pathway inhibition and immune reprogramming, the treatment transforms the suppressive landscape into an immunostimulatory environment, thereby improving anti-tumor immune response efficacy while eliminating immune suppression.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of compositions and methods for modulating MYCT1. An aspect of the present disclosure provides for a method of regulating tumor angiogenesis (anti-angiogenesis, Myct1-targeted vascular control) and/or immunostimulation, which inhibit tumor growth, in a subject. The present disclosure provides methods to quantify MYCT1 to predict responsiveness of a subject having a cancer or tumor to a treatment, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.